{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-072594","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.282013+00:00","generated_at":"2026-05-21T05:16:48.361896+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Aptevo reports 90% remission rate in frontline AML with mipletamig triplet; no CRS","bullets":["9 of 10 frontline AML patients achieved remission with mipletamig + venetoclax + azacitidine across two trials.","RAINIER Cohort 2 fully enrolled; Cohort 3 now open; 5/6 patients in Cohort 1 achieved remission within 30 days.","No cytokine release syndrome observed in ongoing RAINIER trial; favorable safety profile attributed to ADAPTIR format.","Financial results for Q1 2025 reported but no specific figures disclosed in this release."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-072594","json":"https://secwatch.observer/filing/0000950170-25-072594.json","markdown":"https://secwatch.observer/filing/0000950170-25-072594.md","text":"https://secwatch.observer/filing/0000950170-25-072594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025072594/0000950170-25-072594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025072594/apvo-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:16:48.361896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}